ESTEVE's Acquisition of Caprelsa®
ESTEVE has made a significant move in the pharmaceutical landscape by entering into an agreement to acquire the rights for Caprelsa® (vandetanib) across more than 50 countries. This innovative medicine is designed for adults and children over the age of five suffering from aggressive and symptomatic medullary thyroid cancer.
About Medullary Thyroid Cancer
Medullary thyroid carcinoma is a rare and aggressive form of cancer that originates from the parafollicular cells of the thyroid, which produce the hormone calcitonin. Often the standard treatment involves surgery; however, medications such as vandetanib play a critical role in managing the disease. Vandetanib is categorized as a 'protein tyrosine kinase inhibitor,' which functions by inhibiting the activity of enzymes, ultimately reducing blood supply to cancer cells and slowing tumor growth.
Expansion into Specialized Treatments
This acquisition represents a crucial step forward for ESTEVE's growth strategy. The company is dedicated to focusing on specialized therapies that address high unmet medical needs. José María Giménez-Arnau, Chief Scientific & Medical Officer, expressed pride in joining the fight against this challenging form of cancer, emphasizing the company’s commitment to improving the quality of life for patients and their care teams.
Recent Developments in ESTEVE's Portfolio
In addition to the Caprelsa® acquisition, ESTEVE has been expanding its portfolio focused on rare and ultra-rare diseases. In earlier developments, the company successfully acquired a business unit specializing in endocrinology and onco-endocrinology, further highlighting its commitment to highly specialized treatments. Furthermore, ESTEVE has secured licenses for biologic products aimed at treating serious deficiencies in children, reinforcing its reputation as a leader in innovative therapy.
Commitment to Patient Care
According to Jacob Tolstrup, Chief Commercial Officer of ESTEVE, the addition of Caprelsa® serves to enhance the company's existing specialized therapies portfolio. This acquisition is not just a business move but a promise to provide significant advancements in patient care on a global scale. The ability to offer innovative treatments aligns with ESTEVE’s mission to serve patients facing serious health challenges.
Regulatory Clearances
The completion of ESTEVE's acquisition of Caprelsa® is contingent on obtaining the necessary regulatory approvals, which is a customary step in pharmaceutical transactions. The company is working diligently to ensure all requirements are met efficiently.
Frequently Asked Questions
What is Caprelsa® used for?
Caprelsa® (vandetanib) is used to treat aggressive and symptomatic medullary thyroid cancer in adults and children above five years old.
Why is ESTEVE acquiring Caprelsa®?
The acquisition is part of ESTEVE's strategy to enhance its portfolio of specialized treatments, particularly addressing high unmet medical needs globally.
What type of cancer does Caprelsa® target?
Caprelsa® is specifically designed to target medullary thyroid carcinoma, which is a rare type of thyroid cancer.
What are the benefits of using vandetanib?
Vandetanib helps slow down cancer growth by blocking the action of tyrosine kinases, which decrease blood supply to the cancer cells.
What is ESTEVE's commitment to patient care?
ESTEVE is committed to improving patient lives through innovative treatments, focusing on high unmet medical needs in rare and ultra-rare diseases.
